CinnaGen Enters EU Market with EMA Approval for Zandoriah®
Themes
Oncology trial systems debut at SCOPE 2026 as AI adoption accelerates
Biorce secures $52.5m in Series A to expand AI clinical trial tech
Revealing the human and business cost of clinical trial inefficiencies for Data Managers and CRAs
ASH 2025: Eli Lilly’s Jaypirca emerges as a strong first-line contender in CLL/SLL
Redefining clinical trials in oncology and rare diseases across the Europe
ESMO 2025: potential new adjuvant option ensartinib for ALK+ NSCLC
Asbestos-related cancers still prevalent in the UK
